Business Wire

ADVA

22.7.2021 07:02:12 CEST | Business Wire | Press release

Share
ADVA posts record results for Q2 2021

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported record financial results for Q2 2021 ended on June 30, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005791/en/

Q2 2021 financial summary1

(in thousands of EUR)

Q2

Q2

Change

Q1

Change

 

 

2021

2020

 

2021

 

 

 

 

Revenues

149,354

145,024

3.0%

144,473

3.4%

 

Pro forma gross profit

57,274

50,204

14.1%

55,345

3.5%

 

in % of revenues

38.3%

34.6%

3.7pp

38.3%

0.0pp

 

Pro forma operating income

14,415

10,107

42.6%

12,860

12.1%

 

in % of revenues

9.7%

7.0%

2.7pp

8.9%

0.8pp

 

Operating income (loss)

13,036

8,658

50.6%

11,573

12.6%

 

Net income

12,001

7,629

57.3%

11,228

6.9%

 

 

 

(in thousands of EUR)

Jun. 30

2021

Jun. 30

2020

Change

Mar. 31

2021

Change

 

Cash and cash equivalents

85,023

67,586

25.8%

79,060

7.5%

 

Net cash (+) / Net debt (-)

3,876

-44,928

n.a.

-10,626

n.a.

 

Net working capital

132,767

127,917

3.8%

125,785

5.6%

 

1 Potential difference due to rounding

Q2 2021 IFRS financial results

Revenues in Q2 2021 reached EUR 149.4 million, up by 3.4% from EUR 144.5 million in Q1 2021, also up by 3.0% compared to EUR 145.0 million in Q2 2020. As in the first quarter of the fiscal year, this success was particularly due to high order volume from communication service providers as well as private enterprises and governments.

Pro forma gross profit in Q2 2021 increased by 3.5%, reaching EUR 57.3 million (38.3% of revenues) compared to EUR 55.3 million (38.3% of revenues) in Q1 2021 and increased considerably by 14.1% compared to EUR 50.2 million (34.6% of revenues) reported in Q2 2020. Software and service revenue contribution was strong, and the customer and product mix also supported the gross margin growth.

Pro forma operating income for Q2 2021 was EUR 14.4 million (9.7% of revenues) and increased by 12.1% compared to EUR 12.9 million (8.9% of revenues) reported in Q1 2021. Compared to Q2 2020, pro forma operating income improved significantly by 42.6% from EUR 10.1 million (7.0% of revenues).

Operating income for Q2 2021 of EUR 13.0 million increased by 12.6% from EUR 11.6 million reported for Q1 2021 and significantly increased by 50.6% from EUR 8.7 million in Q2 2020.

Net income reached EUR 12.0 million in Q2 2021, up by 6.9% from EUR 11.2 million in Q1 2021, and significantly up by 57.3% from EUR 7.6 million in Q2 2020.

The company’s cash and cash equivalents totaled EUR 85.0 million, representing an increase of EUR 5.9 million compared to EUR 79.1 million at the end of Q1 2021. Year-over-year cash and cash equivalents substantially increased by EUR 17.4 million from EUR 67.6 million at the end of Q2 2020.

Net cash at the end of Q2 2021 stood at EUR 3.9 million when compared to net debt positions of EUR 10.6 million at the end of Q1 2021 or EUR 44.9 million at the end of Q2 2020, respectively. Thus, Q2 2021 was the first quarter showing a net cash position since the introduction of the accounting standard IFRS 16.

Net working capital at quarter-end was EUR 132.8 million and increased by EUR 7.0 million compared to EUR 125.8 million at the end of Q1 2021.

Management commentary

“We continue to grow our business, showing profits and building our financial resources,” said Brian Protiva, CEO, ADVA. “The macro-environment for our industry continues to be good. The digitization efforts in many global regions are in full swing, and the expansion of communication infrastructure is moving at speed. Security is on the top of our customers’ digital agenda, and we are sharpening our profile as the supplier of choice for trusted network infrastructure. With a record-level order backlog, we will continue to use all of our strengths to produce results that allow us to be a leader in a consolidating market.”

“The second quarter of 2021 marked another record quarter in terms of profitability. While continuing to execute our business transformation strategy, we were able to absorb higher purchase prices of components due to the semiconductor crisis and reached a pro forma EBIT of 9.7%,” commented Uli Dopfer, CFO, ADVA. “Also, cash generation was once again very positive. Despite debt repayments of EUR 7.5 million, we were able to increase cash by EUR 6 million and now report a net cash position of EUR 3.9 million also when applying IFRS 16. With that strong first six months in the bank, I am encouraged that we will manage the current supply bottlenecks and reach for the full year a pro forma EBIT between 7% and 10% of revenues.”

Financial outlook 2021

For the fiscal year 2021, ADVA expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 7.0% and 10.0% of revenues.

The company will publish its financial results for Q3 2021 on October 21, 2021.

Conference call details

ADVA will hold a conference call for analysts and investors today, July 22, 2021, to discuss the Q2 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:

https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete half-year report 2021 (January – June) is available as a PDF:

https://www.adva.com/en/about-us/investors/financial-results/financial-statements

A replay of the call will be available here:

https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye